ArcellxACLX
About: Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Employees: 163
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 25
36% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 55
14.94% more ownership
Funds ownership: 92.52% [Q3] → 107.46% (+14.94%) [Q4]
12% more funds holding
Funds holding: 186 [Q3] → 208 (+22) [Q4]
10% more funds holding in top 10
Funds holding in top 10: 10 [Q3] → 11 (+1) [Q4]
7% more capital invested
Capital invested by funds: $4.16B [Q3] → $4.46B (+$301M) [Q4]
8% more call options, than puts
Call options by funds: $35.8M | Put options by funds: $33.3M
Research analyst outlook
We haven’t received any recent analyst ratings for ACLX.
Financial journalist opinion
Based on 3 articles about ACLX published over the past 30 days









